ArticleInfectious diseases in obstetrics and gynecology2014
Performance of BVBlue rapid test in detecting bacterial vaginosis among women in Mysore, India.
Article in Infectious diseases in obstetrics and gynecology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- BVBlue as a diagnostic instrument for the diagnosis of bacterial vaginosis: a systematic review.BMC women's health · 2025Pooled it
- Article
- Diagnostic accuracy of an enzyme-based point-of-care test versus Nugent score for bacterial vaginosis among pregnant women attending routine antenatal care in Zambia.BMC infectious diseases · 2026Article
- Article
- Evaluation of Various Diagnostic Strategies for Bacterial Vaginosis, Including a New Approach Based on MALDI-TOF Mass Spectrometry.Microorganisms · 2024Article
- The role of sialidases in the pathogenesis of bacterial vaginosis and their use as a promising pharmacological target in bacterial vaginosis.Frontiers in cellular and infection microbiology · 2024Review
- Maternal and fetal outcomes of pregnant women with bacterial vaginosis.Frontiers in surgery · 2023Article
- Large-scale characterisation of the pregnancy vaginal microbiome and sialidase activity in a low-risk Chinese population.NPJ biofilms and microbiomes · 2021Article
- Finding a Balance in the Vaginal Microbiome: How Do We Treat and Prevent the Occurrence of Bacterial Vaginosis?Antibiotics (Basel, Switzerland) · 2021Review
- Nanophotonic Sialidase Immunoassay for Bacterial Vaginosis Diagnosis.ACS pharmacology & translational science · 2021Article
- Bacterial Vaginosis: What Do We Currently Know?Frontiers in cellular and infection microbiology · 2021Review
- Bacterial Vaginosis: Current Diagnostic Avenues and Future Opportunities.Frontiers in cellular and infection microbiology · 2020Review
- A Biochemiluminescent Sialidase Assay for Diagnosis of Bacterial Vaginosis.Scientific reports · 2019Article
- Comparison of Amsel criteria, Nugent score, culture and two CE-IVD marked quantitative real-time PCRs with microbiota analysis for the diagnosis of bacterial vaginosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Bacterial vaginosis (BV) is the most common cause of abnormal vaginal discharge in reproductive age women. It is associated with increased susceptibility to HIV/STI and adverse birth outcomes. Diagnosis of BV in resource-poor settings like India is challenging. With little laboratory infrastructure there is a need for objective point-of-care diagnostic tests. Vaginal swabs were collected from women 18 years and older, with a vaginal pH>4.5 attending a reproductive health clinic. BV was diagnosed with Amsel's criteria, Nugent scores, and the OSOM BVBlue test. Study personnel were blinded to test results. There were 347 participants enrolled between August 2009 and January 2010. BV prevalence was 45.1% (95% confidence interval (CI): 41.5%-52.8%) according to Nugent score. When compared with Nugent score, the sensitivity, specificity, positive predictive value, negative predictive value for Amsel's criteria and BVBlue were 61.9%, 88.3%, 81.5%, 73.7% and 38.1%, 92.7%, 82.1%, 63.9%, respectively. Combined with a "whiff" test, the performance of BVBlue increased sensitivity to 64.4% and negative predictive value to 73.8%. Despite the good specificity, poor sensitivity limits the usefulness of the BVBlue as a screening test in this population. There is a need to examine the usefulness of this test in other Indian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.